Making progress: Preserving beta cells in type 1 diabetes

Annals of the New York Academy of Sciences

Volumn 1243, Issue 1, 2011, Pages 119-134

  Gallagher, Mary Pat ^a   Goland, Robin S ^a   Greenbaum, Carla J ^b  

^a College of Physicians and Surgeons ^*  (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune; Beta cell; Prevention; Type 1 diabetes

Indexed keywords

ABATACEPT; ALPHA 1 ANTITRYPSIN; ANTIDIABETIC AGENT; AZATHIOPRINE; BCG VACCINE; CANAKINUMAB; CYCLOSPORIN; ETANERCEPT; HEMOGLOBIN A1C; INSULIN; INSULIN ZINC SUSPENSION; LANSOPRAZOLE; NICOTINAMIDE; OKT 3; OTELIXIZUMAB; PLACEBO; PREDNISONE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SITAGLIPTIN; THYMOCYTE ANTIBODY;

AUTOIMMUNITY; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SYNTHESIS; INSULIN TREATMENT; LYMPHOCYTOPENIA; NEPHROTOXICITY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RISK REDUCTION; UMBILICAL CORD BLOOD;

EID: 84255199280     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06321.x     Document Type: Review

References (74)

1. Unwin, N., D. Gan & D. Whiting. 2010. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. Diabetes Res. Clin. Pract. 87: 2-3.
2. Fourlanos, S., M.D. Varney, B.D. Tait, et al. 2008. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 31: 1546-1549.
3. Garcia-Webb, P., P. Zimmet, A. Bonser, et al. 1984. Factors affecting fasting serum C-peptide levels in Micronesians: comparison with a Caucasoid population. Diabetologia 27: 23-26.
4. The Diabetes Control and Complications Trial Study Group. 1998. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann. Intern. Med. 128: 517-523.
5. Takita, M., S. Matsumoto, H. Qin, et al. 2011. Secretory Unit of Islet Transplant Objects (SUITO) Index can predict severity of hypoglycemic episodes in clinical islet cell transplantation. Cell Transplant. In press.
6. Greenbaum, C.J. 2002. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. Clin. Immunol. 104: 97-104.
7. Feutren, G., L. Papoz, R. Assan, et al. 1986. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2: 119-124.
8. The Canadian European Randomized Control Trial Group. 1988. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37:1574-1582.
9. Skyler, J.S. & A. Rabinovitch. 1992. Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group. J. Diabetes Complicat. 6: 77-88.
10. Jenner, M., G. Bradish, C. Stiller & P. Atkison. 1992. Cyclosporin A treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus. London Diabetes Study Group. Diabetologia 35: 884-888.
11. Pozzilli, P., N. Visalli, M.L. Boccuni, et al. 1994. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group. Diabet. Med. 11: 98-104.
12. Pozzilli, P., N. Visalli, R. Buzzetti, et al. 1995. Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years. Diabete. Metab. 21: 47-49.
13. Rakotoambinina, B., J. Timsit, I. Deschamps, et al. 1995. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Diabetes Care 18: 1487-1490.
14. De Filippo, G., J.C. Carel, C. Boitard & P.F. Bougneres. 1996. Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes 45:101-104.
15. Bougneres, P.F., J.C. Carel, L. Castano, et al. 1988. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N. Engl. J. Med. 318: 663-670.
16. Assan, R., J. Timsit, G. Feutren, et al. 1994. The kidney in cyclosporin A-treated diabetic patients: a long-term clinicopathological study. Clin. Nephrol. 41: 41-49.
17. Eisenbarth, G.S., S. Srikanta, R. Jackson, et al. 1985. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 2: 271-276.
18. Silverstein, J., N. Maclaren, W. Riley, et al. 1988. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 319: 599-604.
19. Cook, J.J., I. Hudson, L.C. Harrison, et al. 1989. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 38: 779-783.
20. Allen, H.F., G.J. Klingensmith, P. Jensen, et al. 1999. Chase. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care 22: 1703-1707.
21. Chaillous, L., H. Lefevre, C. Thivolet, et al. 2000. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356: 545-549.
22. Pozzilli, P., D. Pitocco, N. Visalli, et al. 2000. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 43: 1000-1004.
23. Pozzilli, P., N. Visalli, A. Signore, et al. 1995. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 38: 848-852.
24. Shah, S.C., J.I. Malone & N.E. Simpson. 1989. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N. Engl. J. Med. 320: 550-554.
25. Gale, E.A., P.J. Bingley, C.L. Emmett & T. Collier. 2004. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363: 925-931.
26. Diabetes Prevention Trial-Type 1 Diabetes Study Group. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346: 1685-1691.
27. Skyler, J.S., J.P. Krischer, J. Wolfsdorf, et al. 2005. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 28: 1068-1076.
28. Chatenoud, L., M.F. Baudrihaye, H. Kreis, et al. 1982. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur. J. Immunol. 12: 979-982.
29. Chatenoud, L., E. Thervet, J. Primo & J.F. Bach. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 91: 123-127.
30. You, S., B. Leforban, C. Garcia, et al. 2007. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl. Acad. Sci. U.S.A. 104: 6335-6340.
31. Herold, K.C., W. Hagopian, J.A. Auger, et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346: 1692-1698.
32. Herold, K.C., S.E. Gitelman, U. Masharani, et al. 2005. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763-1769.
33. Herold, K.C., S. Gitelman, C. Greenbaum, et al. 2009. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132: 166-173.
34. Keymeulen, B., E. Vandemeulebroucke, A.G. Ziegler, et al. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352: 2598-2608.
35. Keymeulen, B., M. Walter, C. Mathieu, et al. 2010. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53: 614-623.
36. Sherry, N., W. Hagopian, J. Ludvigsson, et al. 2011. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378: 487-497.
37. AbATE Study (hOKT3γ1(Ala-Ala); teplizumab; Treatment of Type 1 Diabetes-Update on Clinical Trials [Symposia]. 2011. In Proceedings of the 71st Scientific Sessions American Diabetes Association. San Diego, CA.
38. Manno, R. & F. Boin. 2010. Immunotherapy of systemic sclerosis. Immunotherapy 2: 863-878.
39. Pescovitz, M.D., C.J. Greenbaum, H. Krause-Steinrauf, et al. 2009. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361: 2143-2152.
40. Marelli-Berg, F.M., K. Okkenhaug & V. Mirenda. 2007. A two-signal model for T cell trafficking. Trends. Immunol. 28: 267-273.
41. Orban, T., B. Bundy, D.J. Becker, et al. 2011. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378: 412-419.
42. Harrison, L.C. 2008. Vaccination against self to prevent autoimmune disease: the type 1 diabetes model. Immunol. Cell. Biol. 86: 139-145.
43. Nanto-Salonen, K., A. Kupila, S. Simell, et al. 2008. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372: 1746-1755.
44. Vandemeulebroucke, E., F.K. Gorus, K. Decochez, et al. 2009. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab. 35: 319-327.
45. Knip, M. 2009. Diet, gut, and type 1 diabetes: role of wheat-derived peptides? Diabetes 58: 1723-1724.
46. Hummel, S., M. Pfluger, M. Hummel, et al. 2011. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 34: 1301-1305.
47. Knip, M., S.M. Virtanen, D. Becker, et al. 2011. Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR). Am. J. Clin. Nutr. 94: 1814S-1820S.
48. Akerblom, H.K., J. Krischer, S.M. Virtanen, et al. 2011. The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study: recruitment, intervention and follow-up. Diabetologia 54: 627-633.
49. Ludvigsson, J., M. Hjorth, M. Cheramy, et al. 2011. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 54: 634-640.
50. Agardh, C.D., C.M. Cilio, A. Lethagen, et al. 2005. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complicat. 19: 238-246.
51. Wherrett, D.K., B. Bundy, D.J. Becker, et al. 2011. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378: 319-327.
52. GAD65; Treatment of Type 1 Diabetes-Update on Clinical Trials [Symposia]. 2011. In Proceedings of the 71st Scientific Sessions American Diabetes Association. San Diego, CA.
53. Mastrandrea, L., J. Yu, T. Behrens, et al. 2009. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32: 1244-1249.
54. Rabinovitch, A. & J.S. Skyler. 1998. Prevention of type 1 diabetes. Med. Clin. North Am. 82: 739-755.
55. FOCIS. 2011. Rapamycin plus IL-2 combination therapy in T1D subjects enhances IL-1 responsiveness in CD25+ Treg, but also NK and effector T cells [Abstract]. Federation of Clinical Immunology Societies. Washington, DC.
56. American Diabetes Association. 2011. Rapamycin plus IL-2 combination therapy in subjects with T1D results in a sustained increase in IL-2 responsiveness and a transient decrease in C-peptide levels [Abstract]. American Diabetes Association 71st Scientific Sessions. San Diego, CA.
57. Annaloro, C., F. Onida & G. Lambertenghi Deliliers. 2009. Autologous hematopoietic stem cell transplantation in autoimmune diseases. Expert. Rev. Hematol. 2: 699-715.
58. Voltarelli, J.C., C.E. Couri, A.B. Stracieri, et al. 2007. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297: 1568-1576.
59. Couri, C.E., M.C. Oliveira, A.B. Stracieri, et al. 2009. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301: 1573-1579.
60. Sherr, J., J. Sosenko, J.S. Skyler & K.C. Herold. 2008. Prevention of type 1 diabetes: the time has come. Nat. Clin. Pract. Endocrinol. Metab. 4: 334-343.
61. Fourlanos, S., C. Perry, S.A. Gellert, et al. 2011. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60: 1237-1245.
62. Breda, L., M. Del Torto, S. De Sanctis & F. Chiarelli. 2011. Biologics in children's autoimmune disorders: efficacy and safety. Eur. J. Pediatr. 170: 157-167.
63. Saudek, F., T. Havrdova, P. Boucek, et al. 2004. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev. Diabet. Stud. 1: 80-88.
64. Xu, G., D.A. Stoffers, J.F. Habener & S. Bonner-Weir. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276.
65. Li, Y., T. Hansotia, B. Yusta, et al. 2003. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278: 471-478.
66. Drucker, D.J. 2003. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 17: 161-171.
67. Suarez-Pinzon, W.L., R.F. Power, Y. Yan, et al. 2008. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57: 3281-3288.
68. Suarez-Pinzon, W.L., G.S. Cembrowski & A. Rabinovitch. 2009. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 52: 1680-1682.
69. Haller, M.J., H.L. Viener & C. Wasserfall. 2008. Autologous umbilical cord blood infusion for type 1 diabetes. Exp. Hematol. 36: 710-715.
70. Solvason, N., Y.P. Lou, W. Peters, et al. 2008. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J. Immunol. 181: 8298-8307.
71. DiMasi, J.A., R.W. Hansen & H.G. Grabowski. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22: 151-185.
72. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. 2011/01/07 ed. Washington, DC, 2010:85.
73. Kola, I. & J. Landis. 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug. Discov. 3: 711-715.
74. Devendra, D., Liu, E. & Eisenbarth, G.S. 2004. Type 1 diabetes: recent developments. BMJ. 328: 750-754.